drugset / Trial / NCT00057564

A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

NCT00057564

Phase 3 Completed 470 enrolled Celgene Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma

Timeline

Start
2003-02
Primary completion
2006-04
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified 200 mg Oral
Background Dexamethasone Small molecule 40 mg Oral

Indications